A Phase 2 dose ranging trial with ATI-50002 for the topical treatment of patchy alopecia areata.

Trial Profile

A Phase 2 dose ranging trial with ATI-50002 for the topical treatment of patchy alopecia areata.

Planning
Phase of Trial: Phase II

Latest Information Update: 08 Aug 2017

At a glance

  • Drugs ATI 50002 (Primary)
  • Indications Alopecia areata
  • Focus Therapeutic Use
  • Most Recent Events

    • 08 Aug 2017 According to an Aclaris Therapeutics media release, the company has submitted an IND Application to the U.S. FDA. Following FDA clearance of the IND, the company expects to initiate this trial.
    • 20 Mar 2017 New trial record
    • 15 Mar 2017 According to an Aclaris Therapeutics media release, the company plans to initiate this trial in the second half of 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top